Literature DB >> 34095711

Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice.

J Kevin Hicks1,2, Rachel Howard3, Phillip Reisman3, Jacob J Adashek4, Karen K Fields2,5, Jhanelle E Gray2,6, Bryan McIver2,7, Kelly McKee5, Mandy F O'Leary2,8, Randa M Perkins2,9, Edmondo Robinson2,10, Ankita Tandon4, Jamie K Teer2,11, Joseph Markowitz2,12, Dana E Rollison2,13.   

Abstract

Next-generation sequencing (NGS) is rapidly expanding into routine oncology practice. Genetic variations in both the cancer and inherited genomes are informative for hereditary cancer risk, prognosis, and treatment strategies. Herein, we focus on the clinical perspective of integrating NGS results into patient care to assist with therapeutic decision making. Five key considerations are addressed for operationalization of NGS testing and application of results to patient care as follows: (1) NGS test ordering and workflow design; (2) result reporting, curation, and storage; (3) clinical consultation services that provide test interpretations and identify opportunities for molecularly guided therapy; (4) presentation of genetic information within the electronic health record; and (5) education of providers and patients. Several of these key considerations center on informatics tools that support NGS test ordering and referencing back to the results for therapeutic purposes. Clinical decision support tools embedded within the electronic health record can assist with NGS test utilization and identifying opportunities for targeted therapy including clinical trial eligibility. Challenges for project and change management in operationalizing NGS-supported, evidence-based patient care in the context of current information technology systems with appropriate clinical data standards are discussed, and solutions for overcoming barriers are provided.
© 2021 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2021        PMID: 34095711      PMCID: PMC8169076          DOI: 10.1200/PO.20.00513

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


  79 in total

1.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Authors:  Joaquin Mateo; Suzanne Carreira; Shahneen Sandhu; Susana Miranda; Helen Mossop; Raquel Perez-Lopez; Daniel Nava Rodrigues; Dan Robinson; Aurelius Omlin; Nina Tunariu; Gunther Boysen; Nuria Porta; Penny Flohr; Alexa Gillman; Ines Figueiredo; Claire Paulding; George Seed; Suneil Jain; Christy Ralph; Andrew Protheroe; Syed Hussain; Robert Jones; Tony Elliott; Ursula McGovern; Diletta Bianchini; Jane Goodall; Zafeiris Zafeiriou; Chris T Williamson; Roberta Ferraldeschi; Ruth Riisnaes; Bernardette Ebbs; Gemma Fowler; Desamparados Roda; Wei Yuan; Yi-Mi Wu; Xuhong Cao; Rachel Brough; Helen Pemberton; Roger A'Hern; Amanda Swain; Lakshmi P Kunju; Rosalind Eeles; Gerhardt Attard; Christopher J Lord; Alan Ashworth; Mark A Rubin; Karen E Knudsen; Felix Y Feng; Arul M Chinnaiyan; Emma Hall; Johann S de Bono
Journal:  N Engl J Med       Date:  2015-10-29       Impact factor: 91.245

2.  A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Authors:  J Mateo; D Chakravarty; R Dienstmann; S Jezdic; A Gonzalez-Perez; N Lopez-Bigas; C K Y Ng; P L Bedard; G Tortora; J-Y Douillard; E M Van Allen; N Schultz; C Swanton; F André; L Pusztai
Journal:  Ann Oncol       Date:  2018-09-01       Impact factor: 32.976

Review 3.  Prioritizing targets for precision cancer medicine.

Authors:  F Andre; E Mardis; M Salm; J-C Soria; L L Siu; C Swanton
Journal:  Ann Oncol       Date:  2014-10-24       Impact factor: 32.976

Review 4.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.

Authors:  G C Bell; K E Caudle; M Whirl-Carrillo; R J Gordon; K Hikino; C A Prows; A Gaedigk; Jag Agundez; S Sadhasivam; T E Klein; M Schwab
Journal:  Clin Pharmacol Ther       Date:  2017-04-06       Impact factor: 6.875

Review 5.  Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology.

Authors:  Jia Zeng; Amber Johnson; Md Abu Shufean; Michael Kahle; Dong Yang; Scott E Woodman; Thuy Vu; Shhyam Moorthy; Vijaykumar Holla; Funda Meric-Bernstam
Journal:  JCO Clin Cancer Inform       Date:  2019-09

6.  Decision-Making Preferences About Secondary Germline Findings That Arise From Tumor Genomic Profiling Among Patients With Advanced Cancers.

Authors:  Jada G Hamilton; Elyse Shuk; Margaux Genoff Garzon; Vivian M Rodríguez; Joy Westerman; Jennifer L Hay; Kenneth Offit; Mark E Robson
Journal:  JCO Precis Oncol       Date:  2017-12-21

7.  Development and Initial Assessment of a Patient Education Video about Pharmacogenetics.

Authors:  Rachel Mills; Megan Ensinger; Nancy Callanan; Susanne B Haga
Journal:  J Pers Med       Date:  2017-05-25

8.  Return of individual genomic research results: are laws and policies keeping step?

Authors:  Adrian Thorogood; Gratien Dalpé; Bartha Maria Knoppers
Journal:  Eur J Hum Genet       Date:  2019-01-08       Impact factor: 4.246

9.  Development and use of active clinical decision support for preemptive pharmacogenomics.

Authors:  Gillian C Bell; Kristine R Crews; Mark R Wilkinson; Cyrine E Haidar; J Kevin Hicks; Donald K Baker; Nancy M Kornegay; Wenjian Yang; Shane J Cross; Scott C Howard; Robert R Freimuth; William E Evans; Ulrich Broeckel; Mary V Relling; James M Hoffman
Journal:  J Am Med Inform Assoc       Date:  2013-08-26       Impact factor: 4.497

10.  Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).

Authors:  Kelly E Caudle; Henry M Dunnenberger; Robert R Freimuth; Josh F Peterson; Jonathan D Burlison; Michelle Whirl-Carrillo; Stuart A Scott; Heidi L Rehm; Marc S Williams; Teri E Klein; Mary V Relling; James M Hoffman
Journal:  Genet Med       Date:  2016-07-21       Impact factor: 8.822

View more
  3 in total

1.  Tumor and Constitutional Sequencing for Neurofibromatosis Type 1.

Authors:  Schuyler Tong; W Patrick Devine; Joseph T Shieh
Journal:  JCO Precis Oncol       Date:  2022-05

Review 2.  Genomics and Immunomics in the Treatment of Urothelial Carcinoma.

Authors:  Veronica Mollica; Francesco Massari; Alessandro Rizzo; Roberto Ferrara; Arjun K Menta; Jacob J Adashek
Journal:  Curr Oncol       Date:  2022-05-12       Impact factor: 3.109

3.  Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma.

Authors:  Evan J Walker; Dena Goldberg; Kelly M Gordon; Christina Pedley; Julia Carnevale; Pelin Cinar; Eric A Collisson; Margaret A Tempero; Andrew H Ko; Amie M Blanco; Mallika Dhawan
Journal:  Oncologist       Date:  2021-09-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.